MGTX Stock Forecast & Price Target

MeiraGTx Holdings is supported by a compelling pipeline with two near-term value drivers in radiation-induced xerostomia and RPGR-associated XLRP, while AAV-AIPL1 adds an additional rare-disease upside case. The fully enrolled AQUAx2 study is on track for a 2Q27 readout, with a BLA filing mid-’27, potential approval late-’27, and US launch early-’28, while XLRP now anticipates an FDA filing in 2026 and launch in 2027. Financially, the company reported $321m in 2Q26 revenue, ended with $145m in cash, and secured substantial non-dilutive funding through a $400M Oberland package plus $200m upfront from the Parkinson’s partnership, which together strengthens runway and reduces dilution risk.

MeiraGTx Holdings is weighed down by the inherent fragility of a development-stage biotechnology model, where value depends on successful clinical execution rather than recurring product revenue. Its pipeline still faces major uncertainty across clinical progression, regulatory approval, IP protection, and the risk that efficacy or safety data fail to meet expectations, while competition and long-term pricing pressure could further limit future economics. Although the company has end-to-end manufacturing and an estimated enterprise value of about $2.1B with ~$309M in cash, the need to fund trials and the possibility of equity dilution leave the fundamental outlook negative.